International Journal of Science and Research (IJSR)

International Journal of Science and Research (IJSR)
Call for Papers | Fully Refereed | Open Access | Double Blind Peer Reviewed

ISSN: 2319-7064

Downloads: 2 | Views: 65 | Weekly Hits: ⮙1 | Monthly Hits: ⮙1

Case Studies | Cardiology Science | India | Volume 12 Issue 10, October 2023 | Rating: 5.1 / 10


An Observational Study of Rivaroxaban in Thrombotic Coronary Artery Disease

Dr. P. P. Deshmukh [2] | Dr. Raj Ashwini Dwivedi | Dr. Shahryar Khan


Abstract: Introduction: The pathogenesis of acute myocardial infarction (AMI) and unstable angina is the rupture of the coronary artery plaque resulting in acute thrombotic occlusion of a coronary artery. Thus, the thrombus forms an integral part of the atherosclerotic coronary plaques. There is a consensus that intracoronary thrombus makes up a challenging target for revascularization because of its unique characteristics. It has a crucial impact on the performance and outcome of the percutaneous coronary intervention (PCI). Aims and objectives: This study reviews the alternative management of coronary artery thrombus and highlights the role of the oral anticoagulation in its management Materials and methods: We took 60 patients of ACS who underwent CAG suggestive of thrombotic occlusion of coronary arteries. They were prescribed oral anticoagulation along with DAPT and statins and check angiography were done after 15 days. Results: Out of 60 patients, 24 (40%) patients shows complete regression of thrombotic lesions, 18 (30%) patients shows regression of lesions causing decreasing in thrombotic burden, while 16 (26.6%) patients shows no regression of lesion and 2 (3.4%) patients lost to follow up. Conclusion: Oral anticoagulation can be used in thrombotic coronary occlusion.


Keywords: Thrombotic coronary artery disease, Rivaroxaban, Heparin, Coronary angiography, PCI


Edition: Volume 12 Issue 10, October 2023,


Pages: 790 - 794

Rate this Article


Select Rating (Lowest: 1, Highest: 10)

5

Your Comments

Characters: 0


Type Your Registered Email Address below to Rate the Article


Verification Code will appear in 2 Seconds ... Wait

Top